Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Cakir, UlkemHas files: Yes

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study
    (BMC, 2020-01-01) Gucyetmez, Bulent; Atalan, Hakan Korkut; Sertdemir, Ibrahim; Cakir, Ulkem; Telci, Lutfi; Grp, Covid 19 Study
  • Thumbnail Image
    Item
    The frequency and severity of metabolic acidosis related to topiramate
    (SAGE PUBLICATIONS LTD, 2016-01-01) Ture, Hatice; Keskin, Ozgul; Cakir, Ulkem; Bingol, Canan Aykut; Ture, Ugur
    Objective: We planned a cross-sectional analysis to determine the frequency and severity of metabolic acidosis in patients taking topiramate while awaiting craniotomy. Methods: Eighty patients (18 - 65 years) taking topiramate to control seizures while awaiting elective craniotomy were enrolled. Any signs of metabolic acidosis or topiramate-related side effects were investigated. Blood chemistry levels and arterial blood gases, including lactate, were obtained. The severity of metabolic acidosis was defined according to base excess levels as mild or moderate. Results: Blood gas analysis showed that 71\% (n = 57) of patients had metabolic acidosis. The frequency of moderate metabolic acidosis was 56\% (n = 45), while that of mild metabolic acidosis was 15\% (n = 12). A high respiratory rate was reported in only 10\% of moderately acidotic patients. Conclusions: In patients receiving topiramate, baseline blood gas analysis should be performed preoperatively to determine the presence and severity of metabolic acidosis.
  • Thumbnail Image
    Item
    Cofilin-1 as a potential biomarker to evaluate acute kidney injury
    (WALTER DE GRUYTER GMBH, 2019-01-01) Coskun, Abdurrahman; Ucal, Yasemin; Berber, Ibrahim; Cakir, Ulkem; Serteser, Mustafa; Moldur, Derya Emel; Derelioglu, Ecenur Izzete; Yozgatli, Tahir Koray; Ozpinar, Aysel; Unsal, Ibrahim
    Acute kidney injury (AKI) is a worldwide health problem and defined by rapid loss of excretory function of the kidney with the accumulation of metabolic end products. For effective treatment and prevent complications the early diagnosis of AKI is crucial. The current analytes used to diagnose AKI are not adequately sensitive and specific and therefore clinicians need new biomarkers. One of the new promising biomarker candidates of renal injury is cofilin-1. Previously, in our laboratory we isolated cofilin-1 in kidney preservation solution prior to transplantation and attempted to measure serum cofilin-1 in renal transplanted patients. However, cofilin-1 was not accurately measured in serum samples due to the methodological issues. In this mini-review, we summarized the current knowledge and concepts both in the literature and our experiences with cofilin-1 as a potential biomarker for the diagnosis and management of AKI.